{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:30:20Z","timestamp":1778902220113,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41575-026-01184-x","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T09:58:45Z","timestamp":1771840725000},"page":"376-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatitis C elimination: is it time to redefine the goals?"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-5318","authenticated-orcid":false,"given":"Yasser","family":"Fouad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-1900","authenticated-orcid":false,"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-3189","authenticated-orcid":false,"given":"Robert G.","family":"Gish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-4144","authenticated-orcid":false,"given":"Mohammed","family":"Eslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"1184_CR1","unstructured":"World Health Organization. Hepatitis C. WHO https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c (2025)."},{"key":"1184_CR2","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2025.02.041","volume":"83","author":"Y S\u00e1nchez-Torrijos","year":"2025","unstructured":"S\u00e1nchez-Torrijos, Y. et al. Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C. J. Hepatol. 83, 652\u2013661 (2025).","journal-title":"J. Hepatol."},{"key":"1184_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.21037\/hbsn-23-562","volume":"13","author":"Z Pan","year":"2024","unstructured":"Pan, Z. et al. A literature review of genetics and epigenetics of HCV-related hepatocellular carcinoma: translational impact. Hepatobiliary Surg. Nutr. 13, 650\u2013661 (2024).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"1184_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/apt.16346","volume":"53","author":"Y Fouad","year":"2021","unstructured":"Fouad, Y. et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Aliment. Pharmacol. Ther. 53, 1080\u20131089 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1184_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S1665-2681(19)31462-0","volume":"11","author":"MA Khattab","year":"2012","unstructured":"Khattab, M. A. et al. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Ann. Hepatol. 11, 487\u2013494 (2012).","journal-title":"Ann. Hepatol."},{"key":"1184_CR6","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/kjm2.12275","volume":"36","author":"C-F Huang","year":"2020","unstructured":"Huang, C.-F. et al. Cure or curd: modification of lipid profiles and cardio\u2010cerebrovascular events after hepatitis C virus eradication. Kaohsiung J. Med. Sci. 36, 920\u2013928 (2020).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"1184_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","volume":"19","author":"M Eslam","year":"2025","unstructured":"Eslam, M. et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol. Int. 19, 261\u2013301 (2025).","journal-title":"Hepatol. Int."},{"key":"1184_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.20517\/mtod.2025.04","volume":"5","author":"S Zerehpooshnesfchi","year":"2025","unstructured":"Zerehpooshnesfchi, S. et al. Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence. Metab. Target Organ Damage 5, 15 (2025).","journal-title":"Metab. Target Organ Damage"},{"key":"1184_CR9","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3350\/cmh.2025.0292","volume":"31","author":"M Witte","year":"2025","unstructured":"Witte, M. et al. Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy. Clin. Mol. Hepatol. 31, 1269\u20131284 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"1184_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008181","volume":"15","author":"S Perez","year":"2019","unstructured":"Perez, S. et al. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet. 15, e1008181 (2019).","journal-title":"PLoS Genet."},{"key":"1184_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51698-8","volume":"15","author":"A Mukherji","year":"2024","unstructured":"Mukherji, A. et al. An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infection. Nat. Commun. 15, 7486 (2024).","journal-title":"Nat. Commun."},{"key":"1184_CR12","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1111\/liv.14666","volume":"40","author":"G Shiha","year":"2020","unstructured":"Shiha, G. et al. GES: a validated simple score to predict the risk of HCC in patients with HCV\u2010GT4\u2010associated advanced liver fibrosis after oral antivirals. Liver Int. 40, 2828\u20132833 (2020).","journal-title":"Liver Int."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01184-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01184-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01184-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:03:22Z","timestamp":1777550602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01184-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1184"],"URL":"https:\/\/doi.org\/10.1038\/s41575-026-01184-x","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"23 February 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.G.G. declares consultancy honoraria from Gilead. M.-L.Y. receives research support from Abbvie, Abbott Diagnostic, Boehringer Ingelheim, BMS, Gilead, Novo Nordisk and Roche diagnostics, serves as a consultant for Abbvie, Abbott Diagnostic, BMS, Gilead, Novo Nordisk, Roche and Roche diagnostics, and has acted as a speaker for Abbvie, BMS, Eisai, Gilead, Roche and Roche diagnostics. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}